Brief: Arvinas Announces Positive Phase 1 Data For Arv-102 Showing Greater Than 50% Lrrk2 Degradation In The Csf Of Patients With Parkinson’S Disease Treated For 28 Days
18/03/2026 11:23
March 18 (Reuters) - Arvinas Inc ARVN.O: ARVINAS ANNOUNCES POSITIVE PHASE 1 DATA FOR ARV-102 SHOWING GREATER THAN 50% LRRK2 DEGRADATION IN THE CSF OF PATIENTS WITH PARKINSON’S DISEASE TREATED FOR 28 DAYS ARVINAS INC - NO SERIOUS ADVERSE EVENTS, DISCONTINUATIONS, OR DEATHS REPORTED WITH ARV-102 ARVINAS INC: ARV-102 WAS WELL TOLERATED ACROSS ALL DOSE LEVELS FOLLOWING 28 DAYS OF ONCE-DAILY DOSING ARVINAS INC - PLANS PHASE 1B TRIAL OF ARV-102 IN PSP IN Q2 2026 Source text: ID:nGNXjkdw0 Further company coverage: ARVN.O ((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on Arvinas
See all newsBrief: Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Arvinas Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Arvinas - Pfizer, And Rigel Receive Hart-Scott-Rodino Clearance For License Agreement On June 11, 2026
Brief: Arvinas - Announces Re-Prioritization Of Portfolio Following Strategic Review - SEC Filing
U.S. RESEARCH ROUNDUP- Cisco, DTE Energy, Marvell Technology